SEARCH

SEARCH BY CITATION

References

  • 1
    MallingH-J, WeekeB (editors). EAACI position paper: immunotherapy. Allergy 1993;48(Suppl. 14):735.
  • 2
    BousquetJ, LockeyR, MallingH-J (editors). WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53(Suppl. 44):142.
  • 3
    Des-Roches A, Paradis L, Knani J, Hejjaoui A, Dhivert H, Chanez P et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996;51: 430433.
  • 4
    Jacobsen L, Nuchel PB, Wihl JA, Lowenstein H, Ipsen H. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy 1997;52: 914920.
  • 5
    Naclerio RM, Proud D, Moylan B, Balcer S, Freidhoff L, Kagey-Sobotka A et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol 1997;100: 293300.
  • 6
    Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341: 468475.
  • 7
    Des-Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997;99: 450453.
  • 8
    Möller C, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study) J Allergy Clin Immunol 2002;109: 251256.
  • 9
    Malling HJ. Immunotherapy as an effective tool in allergy treatment. Allergy 1998;53: 461472.
  • 10
    Bousquet J, Van Cauvenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108: 147334.
  • 11
    Stewart GE, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992;90: 567578.
  • 12
    Malling HJ, Abreu-Nogueira J, Alvarez-Cuesta E, Bjorksten B, Bousquet J, Caillot D et al. Local immunotherapy. Allergy 1998;53: 933944.
  • 13
    Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 1990;18: 277284.
  • 14
    Sabbah A, Hassoun S, Le Sellin J, Andre C, Sicard H. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994;49: 309313.
  • 15
    Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol (Madr) 1995;23: 224230.
  • 16
    Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. J Investig Allergol Clin Immunol 1995;5: 2530.
  • 17
    Quirino T, Iemoli E, Siciliani E, Parmiani S, Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996;26: 12531261.
  • 18
    Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 1997;8: 2127.
  • 19
    Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela G et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998;351: 629632.
  • 20
    Clavel R, Bousquet J, Andre C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 1998;53: 493498.
  • 21
    Horak F, Stubner P, Berger UE, Marks B, Toth J, Jager S. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. J Investig Allergol Clin Immunol 1998;8: 165171.
  • 22
    Vourdas D, Syrigou E, Potamianou P, Carat F, Batard T, Andre C et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998;53: 662672.
  • 23
    Hordijk GJ, Antvelink JB, Luwema RA. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study. Allergol Immunopathol (Madr) 1998;26: 234240.
  • 24
    Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999;54: 249260.
  • 25
    Mungan D, Misirligil Z, Gurbuz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma – a placebo controlled study. Ann Allergy Asthma Immunol 1999;82: 485490.
  • 26
    La Rosa M, Ranno C, Andre C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999;104: 425432.
  • 27
    Pradalier A, Basset D, Claudel A, Couturier P, Wessel F, Galvain S, et al. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 1999;54: 819828.
  • 28
    Purello-D'Ambrosio F, Gangemi S, Isola S, La Motta N, Puccinelli P, Parmiani S et al. Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both. Allergy 1999;54: 968973.
  • 29
    Passalacqua G, Albano M, Riccio A, Fregonese L, Puccinelli P, Parmiani S et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999;104: 964968.
  • 30
    Guez S, Vatrinet C, Fadel R, Andre C. House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 2000;55: 369375.
  • 31
    Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000;55: 842849.
  • 32
    Cafferelli C, Sensi LG, Marcucci F, Cavagni G. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy 2000;55: 11421147.
  • 33
    Bahceciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001;32: 4955.
  • 34
    Voltolini S, Modena P, Minale P, Bignardi D, Troise C, Puccinelli P, Parmiani S. Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule. Allergol Immunopathol (Madr) 2001;29: 103110.
  • 35
    Moller C, Dreborg S, Lanner A, Bjorksten B. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study. Allergy 1986;41: 271279.
  • 36
    Bjorksten B, Moller C, Broberger U, Ahlstedt S, Dreborg S, Johansson SGO et al. Clinical and immunological effects of oral immunotherapy with a standardized birch pollen extract. Allergy 1986;41: 290295.
  • 37
    Taudorf E, Laursen LC, Lanner A, Björksten B, Dreborg S, Søborg M et al. Oral immunotherapy in birch pollen hay fever. J Allergy Clin Immunol 1987;80: 153161.
  • 38
    Cirla AM, Sforza N, Roffi GP, Alessandrini A, Stanizzi R, Dorigo N et al. Preseasonal intranasal immunotherapy in birch-alder allergic rhinitis. A double-blind study. Allergy 1996;51: 299305.
  • 39
    Andri L, Senna G, Betteli C, Givanni A, Andri G, Dimitri G et al. Local nasal immunotherapy with extracts in powdered form is effective and safe in grass pollen rhinitis: a double-blind study. J Allergy Clin Immunol 1996;97: 3441.
  • 40
    Balda BR, Wolf H, Baumgarten C, Klimek L, Rasp G, Kunkel G et al. Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens. Allergy 1998;53: 740748.
  • 41
    Klimek L, Dormann D, Jarman ER, Cromwell O, Riechelmann H, Reske-Kunz AB. Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis. Clin Exp Allergy 1999;29: 13261335.
  • 42
    Winther L, Moseholm L, Mosbech H, Malling H-J. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. I. Efficacy estimated by a model reducing the bias of annual differences in pollen counts. Allergy 2000;55: 818826.
  • 43
    Rak S, Heinrich C, Jacobsen L, Scheynius A, Venge P. A double-blind, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol 2001;108: 921928.
  • 44
    Bødtger U, Poulsen LK, Jacobi H, Malling H-J. The safety and efficacy of subcutaneous birch pollen immunotherapy – a one-year, randomised, double-blind, placebo-controlled study. Allergy 2002;57: 297305.
  • 45
    Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ 1995;311: 11451148.
  • 46
    Taves DR. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Therap 1974;15: 443453.
  • 47
    Stewart AL, Hays RD, Ware JE. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988;26: 724735.
  • 48
    Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30: 473483.
  • 49
    McHorney CA, Ware JE, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31: 247263.
  • 50
    Pedersen BV, Moseholm L. Precision of the daily pollen counts. Identifying sources of variation using variance component models. Aerobiologica 1993;9: 1526.
  • 51
    Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302: 265269.
  • 52
    Frew AJ, White PJ, Smith HE. Sublingual immunotherapy. J Allergy Clin Immunol 1999;104: 267270.
  • 53
    Bousquet J, Scheinmann P, Guinnepain MT et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999;54: 249260.
  • 54
    Passalacqua G, Canonica GW. Allergen-specific sublingual immunotherapy for respiratory allergy. BioDrugs 2001;15: 509519.
  • 55
    Frew AJ, White PJ, Smith HE. Sublingual immunotherapy. J Allergy Clin Immunol 2001;107: 441444.